Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
about
The epigenetic basis of diffuse large B-cell lymphomaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewIntegrative systems medicine approaches to identify molecular targets in lymphoid malignanciesEpigenetic roles in the malignant transformation of gastric mucosal cellsCorrelation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer.Inhibiting DNA Methylation by 5-Aza-2'-deoxycytidine ameliorates atherosclerosis through suppressing macrophage inflammation.6-Thioguanine and zebularine down-regulate DNMT1 and globally demethylate canine malignant lymphoid cells.Chromatin Memory in the Development of Human CancersEpigenetic silencing of TFPI-2 in canine diffuse large B-cell lymphomaSex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells.Epigenomic evolution in diffuse large B-cell lymphomasDUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphomaZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.Ex vivo engineered immune organoids for controlled germinal center reactions.Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.The Impact of DNA Methylation in Hematopoietic Malignancies.Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma.Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphomaAn Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder CancerComplete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies.Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.Genetic and molecular targets in lymphoma: implications for prognosis and treatment.Histone deacetylases 1 and 2 regulate DNA replication and DNA repair: potential targets for genome stability-mechanism-based therapeutics for a subset of cancers.Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy.Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells.Epigenetic dysregulation in follicular lymphoma.Epigenetics: A primer for clinicians.Epigenetic Determinants of Cancer.Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphomaAssociation of downregulation of WWOX with poor prognosis in patients with intrahepatic cholangiocarcinoma after curative resection.DNA Methyltransferase Inhibitors: Development and Applications.Genetic background and evolution of relapses in aggressive B-cell lymphomas.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas
P2860
Q26852288-970A4262-D90D-421B-8E63-B89D819BB0A7Q27304386-20FB7310-4502-4CF7-9C8C-2FFDEE611190Q28067817-72AECACB-34C3-45B8-B388-4A6DD7BCD44EQ28070086-E0F0F308-6131-4279-9B06-52CF7374C927Q34483455-ACF1A4F8-86CD-42D6-A3D6-48AB3B41A6A3Q34551679-A4945F99-FDA1-42B5-B2AC-A5225047AEBCQ34748281-436948FA-452B-487A-8388-8155B3394221Q34979975-34AD9628-6272-4217-8391-BAEAFA287BD3Q35138335-9F13A083-9014-4017-AE9C-C0E551E21EDEQ35262038-01A37FC6-9F04-4EA1-9B81-93A44C98DC08Q35543203-682DE5CA-6522-4A44-9519-EBE14C261850Q35568457-4839689E-74B8-4CDF-867A-135FC32B1A27Q35695410-B01886F0-3D5C-45C4-9D64-9E4D3E05D8AEQ35812007-934E2E97-A3C3-48F7-BD17-2AFDA631AD70Q36020841-7D804001-E711-4EBC-9852-EC6FEB1ACA4BQ36724810-9C5317C2-4FCA-429F-B6EB-9232AE01E323Q36871785-9625E9F7-34DC-4D18-BE5E-C15286C2F809Q37117964-C61F3CFD-04BB-4CB5-AB78-B2D0AAE89D9CQ37240290-A14F33E5-C3F1-4BB5-B2BB-B9D96B521413Q37290684-80D851C4-4C2E-4A64-8597-C60A68A65025Q37594238-AD8337BE-06AF-4671-A230-B6A9910B63A0Q38214120-5E321D66-350E-43A3-A49A-B62D98496CBFQ38240579-9B35269A-7796-432B-80A4-EBFDF126A054Q38294626-960076F0-E623-4800-9918-198F45E196D4Q38459887-3BCDF009-0F8C-4982-BF9D-50BD5C82A0F0Q38504989-FA2AE90F-ECA5-4E1B-AC20-8B776EEB7E34Q38542620-563A89DF-4206-4B32-8001-767C7B74EEFEQ38664822-0B0AC43A-AEE3-41C0-B5D8-C16BCEECAD01Q38668222-D3BC6853-89DF-4FE2-9499-2FB23204122FQ38677466-0F231482-7697-419C-9D4C-E9C237F55DEDQ38770916-1054BF11-C327-44DA-84D8-2A2D6244467CQ38837858-6271D957-900C-444F-9462-6B94C103E411Q38882112-87B6AAD6-3EAA-42B9-AFF0-E7B5B76A93AFQ38918235-62CAA944-FDCE-4C0B-BBCF-2A43DEA3BE03Q38962085-3E405785-9F98-4020-B646-8FE4911DB1BAQ39003558-36FF2D37-DBF8-46B6-945D-BE502EF8BF26Q39336821-77160003-BFF5-48F9-B2CD-418E6AF08096Q39381251-F98DAEBA-ACAA-44E0-83EA-E8DB2D848A33Q39520264-FE2E64F7-F8A2-4F92-8AEB-22F76F564E49Q40974570-D2FC7E9F-F265-4992-8016-EF5D41142744
P2860
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
@en
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
@nl
type
label
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
@en
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
@nl
prefLabel
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
@en
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
@nl
P2093
P2860
P50
P1433
P1476
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
@en
P2093
Amy Chadburn
Aparna Vasanthakumar
Ari Melnick
Biljana Culjkovic
David W Scott
Fabrizio Tabbo
Giorgio Inghirami
John P Leonard
Katherine L Borden
Lucy A Godley
P2860
P304
P356
10.1158/2159-8290.CD-13-0117
P577
2013-08-16T00:00:00Z